Unknown

Dataset Information

0

Repurposing Benzimidazoles against Causative Agents of Chromoblastomycosis: Albendazole Has Superior In Vitro Activity Than Mebendazole and Thiabendazole.


ABSTRACT: Chromoblastomycosis (CBM) is a neglected human implantation mycosis caused by several dematiaceous fungal species. Currently available therapy is usually associated with physical methods, especially surgery, and with high refractoriness. Therefore, drug discovery for CBM is essential. Drug repositioning is a strategy used to facilitate the discovery of new treatments for several diseases. The aim of this study was to discover substances with antifungal activity against CBM agents from a collection of drugs previously approved for use in human diseases. A screening was performed with the NIH Clinical Collection against Fonsecaea pedrosoi. Ten substances, with clinical applicability in CBM, inhibited fungal growth by at least 60%. The minimum inhibitory concentration (MIC) of these substances was determined against other CBM agents, and the benzimidazoles albendazole, mebendazole and thiabendazole presented the lowest MIC values. The selectivity index, based on MIC and cytotoxicity of these substances, revealed albendazole to be more selective. To investigate a possible synergism of this benzimidazole with itraconazole and terbinafine, the chequerboard method was used. All interactions were classified as indifferent. Our current results suggest that benzimidazoles have repositioning potential against CBM agents. Albendazole seems to be the most promising, since it presented the highest selectivity against all dematiaceous fungi tested.

SUBMITTER: Coelho RA 

PROVIDER: S-EPMC10381309 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Repurposing Benzimidazoles against Causative Agents of Chromoblastomycosis: Albendazole Has Superior In Vitro Activity Than Mebendazole and Thiabendazole.

Coelho Rowena Alves RA   Figueiredo-Carvalho Maria Helena Galdino MHG   Almeida-Silva Fernando F   de Souza Rabello Vanessa Brito VB   de Souza Gabriela Rodrigues GR   Sangenito Leandro Stefano LS   Joffe Luna Sobrino LS   Santos André Luis Souza Dos ALSD   da Silva Lourenço Maria Cristina MC   Rodrigues Marcio L ML   Almeida-Paes Rodrigo R  

Journal of fungi (Basel, Switzerland) 20230716 7


Chromoblastomycosis (CBM) is a neglected human implantation mycosis caused by several dematiaceous fungal species. Currently available therapy is usually associated with physical methods, especially surgery, and with high refractoriness. Therefore, drug discovery for CBM is essential. Drug repositioning is a strategy used to facilitate the discovery of new treatments for several diseases. The aim of this study was to discover substances with antifungal activity against CBM agents from a collecti  ...[more]

Similar Datasets

| S-EPMC8255490 | biostudies-literature
| S-EPMC4916931 | biostudies-other
2019-04-30 | GSE130466 | GEO
| S-EPMC5038309 | biostudies-literature
| S-EPMC4297232 | biostudies-literature
| S-EPMC8046409 | biostudies-literature
| S-EPMC5377441 | biostudies-literature
| S-EPMC9321754 | biostudies-literature
| S-EPMC321686 | biostudies-literature
| S-EPMC4096024 | biostudies-literature